drugset / Trial / NCT01360164
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia
Phase 1/2
Unknown
20 enrolled
Shenzhen Beike Bio-Technology Co., Ltd.
Nanjing Medical University · collabNanjing University Medical College Affiliated Wuxi Second Hospital · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabThe Second Hospital of Nanjing Medical University · collabXuzhou Medical University · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The Hereditary Ataxias are a group of genetic disorders characterized by slowly progressive incoordination of gait and often associated with poor coordination of hands, speech, and eye movements. Current treatments for Hereditary Ataxias are mainly pharmacological, rehabilitative, or psychological treatments,while no effective treatment available. Stem Cell therapy is a novel and promising therapeutic strategy for Hereditary Ataxias treatment. In this study, the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells transplantation will be evaluated in patients with Hereditary Ataxias.
Timeline
- Start
- 2010-01
- Primary completion
- 2012-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human umbilical cord mesenchymal stem cells | Cell therapy | — | Intravenous |